Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
JTO Clinical and Research Reports|March 16, 2023
Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and OsimertinibClayton P Smith, Michael Xiang, Stephanie M Yoon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung CancerEdward B Garon, Alexander I Spira, Melissa Johnson, et al.JTO Clinical and Research Reports|August 11, 2025
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed AnalysisJay M Lee, Alessandro Brunelli, Amy L Cummings, et al.The Oncologist|September 27, 2025
Characteristics of clinical trials associated with appeal and return on investment to participants: a review and frameworkMaria J Fernandez Turizo, Maria A Velez, Beth Glenn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 14, 2023
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future PerspectivesJay M Lee, Ciaran J McNamee, Eric Toloza, et al.JTO Clinical and Research Reports|November 25, 2022
The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective StudyDavid J Benjamin, Shuai Chen, Joanna B Eldredge, et al.Lung Cancer (Amsterdam, Netherlands)|September 10, 2021
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLCNanruoyi Zhou, Maria A Velez, Benjamin Bachrach, et al.Nature|August 2, 2023
Consent document translation expense hinders inclusive clinical trial enrolmentMaria A Velez, Beth A Glenn, Maria Garcia-Jimenez, et al.Nature Cancer|February 5, 2022
Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44Amy L Cummings, Jaklin Gukasyan, Henry Y Lu, et al.Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.Pageof 3